EQRx, Inc. (EQRX)
$1.71
Rating:
Recommendation:
-
| Symbol | EQRX |
|---|---|
| Price | $1.71 |
| Beta | 0.000 |
| Volume Avg. | 2.04M |
| Market Cap | 833.384M |
| Shares () | - |
| 52 Week Range | 1.58-6.05 |
| 1y Target Est | - |
| DCF Unlevered | EQRX DCF -> | |
|---|---|---|
| DCF Levered | EQRX LDCF -> | |
| ROE | -11.64% | Sell |
| ROA | -11.62% | Sell |
| Operating Margin | - | |
| Debt / Equity | 4.76% | Neutral |
| P/E | -3.35 | Strong Sell |
| P/B | 0.59 | Buy |
Latest EQRX news
About
Download (Excel)EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC. Its other programs in pipeline include clinical and pre-clinical stage assets, which comprise Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which is in Phase II clinical trials in patients with metastatic breast cancer; EQ176, an anti-programmed death-1 antibody that is in Phase III trials for the treatment of patients with primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor that is in various Phase I trials. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.